Johnson & Johnson announces a $2 billion North Carolina manufacturing expansion as part of a broader U.S. onshore ...

Johnson & Johnson said Thursday it will invest $2 billion in North Carolina to expand U.S. manufacturing, according to ...

With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030.

Longer-term data show that donanemab’s cognitive benefits continue to grow over time, and earlier initiation reduces the risk for progression, with no new safety signals.

Viking Therapeutics' stock drops 40% despite strong Phase 2 weight-loss drug results. See here to know why I remain ultra ...

In a study published in Molecular Metabolism, University of Michigan researchers have shown that a specific population of ...

As the world’s population ages at an unprecedented rate, the field of longevity research is surging to the forefront of ...

In vivo CAR T-cell therapies promise to revolutionize cancer treatment, enhancing access and reducing costs while addressing ...

Viking's key drug demonstrated excellent body weight reduction data in a phase 2 trial, but its safety and tolerability data ...

Novo Nordisk may pursue layoffs as its new CEO focuses on efficiency while facing intensifying obesity drug competition.

Eli Lilly's top neuroscience executive, Anne White, is retiring after three decades with the drugmaker. Eli Lilly on Wednesday said White will remain in her post as executive vice president and ...

In a study known as CROWNS-2 published in JAMA, the researchers randomly assigned 180 adults with CRSwNP to stapokibart (300 ...